All News
Ahmadzay et al. Real world secukinumab in PsA data in 1202 patients. Smokers/ex-smokers have 30% lower treatment retention. But if they maintain treatment, appear to respond equally well. BMI no effect. @RheumNow #ACR24 Abstr#2350 https://t.co/XVPmEBbRu8 https://t.co/QyJirWRKvq
Links:
Richard Conway RichardPAConway ( View Tweet)
A#2291
ESSDAI does not correlate to PROMISE (pt outcomes) in Sjogrens
Symptomatology is complex in SjD and beyond traditional disease activity markers
@RheumNow #ACR24 https://t.co/AhstAFjOVS
Eric Dein ericdeinmd ( View Tweet)
Abstract 1873: The impact of urbanization on lupus nephritis mortality is complex.
Race/ethnicity + income modify the effects
- Income ≥$50k + living in suburbs associated with lower odds of mortality due to LN in racial/ethnic minorities
@RheumNow #ACR24
Akhil Sood MD AkhilSoodMD ( View Tweet)
Abstract 1925: Caution w/ ADI as proxy for neighborhood disadvantage
- ↑ ADI didn’t correlate with ER visits or hospitalizations, but ↓ Childhood Opportunity Index (COI) did:
ER visits: aOR 2.85 (95%CI 1.12-7.26)
Hospitalizations: aOR 4.15 (95%CI 1.25-13.81)
@RheumNow #ACR24 https://t.co/dVZi8oqBnI
Akhil Sood MD AkhilSoodMD ( View Tweet)
Harkins @DrTrishHarkins et al. Impact of AC joint OA in PMR. 67% of PMR have AC joint OA. Those who do have worse pain and fatigue scores. @RheumNow #ACR24 Abstr#1974 https://t.co/vAqVuQ5Jzm https://t.co/zx5MMtWdBE
Links:
Richard Conway RichardPAConway ( View Tweet)
US biosimilar exp
Interchangeable biosimilar - can substitute for reference product wo consulting MD
Primary endpt: pharmacokinetic data
61 approved biosimilars
@RheumKay: “pts should share in financial benefits”
Currently 5-87% discount
#PBMReform @ACRheumDC
@RheumNow #ACR24 https://t.co/RqwbZalZko
Links:
Eric Dein ericdeinmd ( View Tweet)
In their cohort, Dr. Abarza et al reported a small percentage of pts developing PsA before Pso (8.6%)
This group also had faster radiographic progression vs. the Pso before PsA group.....something to consider when evaluating these pts.
@rheumnow #ACR24 abs2328 https://t.co/YPcAaKFS2I
sheila RHEUMarampa ( View Tweet)
Quote of the day. “Time is kidney” Maria Dall’Era MD, UCSF at the ACR SLE guidelines for management of lupus nephritis @RheumNow #ACR24 https://t.co/rz9AhPS2cl
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
A study investigating weight trends in Psoriatic Arthritis (PsA) and the impact of various medications. Analyzing 1754 patients, it explored multifactorial influences on weight changes
Key findings:
- Significant weight loss after starting IL17i, IL23i, and csDMARDs.
- TNFi &… https://t.co/qOl2ojV9rL https://t.co/Eh2ZNLeKhn
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#2286🔬Certolizumab Pegol (CZP) in High RF RA
📊Pooled analysis;N=1180
💥PBO: High RF=more radiographic progression v low RF (Wk24 6.5 v 2.8%,Wk52 17.6 v 10.4%)
💥CZP: min. progression regardless of RF (Wk24 0 v 1.1%;Wk52 5.3 v 3.1%)
#ACR24 @RheumNow https://t.co/koel7SDsUb
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Triboulet et al. JAKi in RA-ILD. 42 patients. Stability of PFTs over median 21 months. HRCT stable in 62%. Progressive ILD on HRCT in 19%. @RheumNow #ACR24 Abstr#2249 https://t.co/PY9BrCfNHc https://t.co/r8fIgrjyDu
Links:
Richard Conway RichardPAConway ( View Tweet)
Tesser et al. Implanted cervical vagus nerve stimulator for b/tsDMARD-IR RA. 242 patients. ACR20 week 12 35% vs 24%. Higher rates of DAS28-CRP LDA/remission. @RheumNow #ACR24 Abstr#L10 https://t.co/OXojHEMkKQ https://t.co/XSt97u7LrR
Links:
Richard Conway RichardPAConway ( View Tweet)
Long COVID outcomes in Autoimmune diseases (AID)
Abstract 1897:
- Long COVID symptoms higher among AID pts vs controls
- vaccinated may have protective benefit
@RheumNow #ACR24 https://t.co/2SEcbkxfcU
Links:
Akhil Sood MD AkhilSoodMD ( View Tweet)
Abstract 1915: Barriers to repro health discussions in rheumatology clinic
- Spanish speaking & IA patients report language differences + OB/GYN deferrals as barriers
Appointment time, clinician knowledge, or patient comfort did not make a difference
@RheumNow #ACR24
Akhil Sood MD AkhilSoodMD ( View Tweet)
Important study in SLE: out of 590 pts with pericarditis, 20% had recurrence w/in 1 year
Higher in early dx, younger pts, higher dx activity, & pred exposure
Is prednisone risk confounding by indication? Or causative?
#ACR24 @RheumNow @andreafava Abstr#2372 https://t.co/Seyi4F6weY
Links:
Mike Putman EBRheum ( View Tweet)
@DianeLacaille Canadian biosimilar exp
Biosimilar transition v originator controls x2 yrs
Weighted model: no decr in ETN biosimilar discontinuation v originator. IFX shows slight decrease - NOT statistical signif
Safety- no difference, slight incr rheum visits
@RheumNow #ACR24 https://t.co/0GMfLAyzOo
Eric Dein ericdeinmd ( View Tweet)
Ren et al. XG005, compound with NSAID and neuropathic like effects, in knee OA. At week 4 significant improvements in WOMAC pain, stiffness, function, and primary endpoint of walking pain @RheumNow #ACR24 Abstr#L08 https://t.co/gQDwAmzI4G https://t.co/b22XC7rXnE
Links:
Richard Conway RichardPAConway ( View Tweet)
Depressing finding re:glucocorticoid discontinuation in SLE
No improvement over decades in rate of GC discontinuation; if anything, we start more GC than ever
@AliDuarteMD help me out here; why haven't we made more progress?
#ACR24 @RheumNow Abstr#2421 https://t.co/uzZATKPWVC
Links:
Mike Putman EBRheum ( View Tweet)
A study evaluating the effectiveness of Direct-to-Patient (D2P) screening for psoriatic arthritis (PsA) in psoriasis patients.
Key findings:
- 30% response rate from 825 patients; 13% screened positive.
- 75% of referrals deemed appropriate, with one-third receiving a new PsA… https://t.co/bcQN6KkC8m https://t.co/zogI2PYvtO
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Cardiology is on!
Dr. Olin discusses Fibromuscular Dysplasia findings on imaging
Definite: string of beads and/or focal narrowing in right setting / location
Possible but nonspecific: dissection, ecstasia, aneurysm, and tortuously
@RheumNow #ACR24 https://t.co/Dr81KQfLSf
Brian Jaros, MD Dr_Brian_MD ( View Tweet)